FindTrial
Sign In

A phase I and pharmacokinetic study to determine the safety of ET-743 administered as a continuous intravenous infusion over 24 hours every 21 days in patients with soft tissue sarcoma.

A phase I and pharmacokinetic study to determine the safety of ET-743 administered as a continuous intravenous infusion over 24 hours every 21 days in patients with soft tissue sarcoma.

Status
Unknown
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221134
Enrollment
Unknown
Registered
2010-06-22
Start date
2010-06-22
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Soft tissue sarcoma

Interventions

investigational material(s) Generic name etc : ET-743 INN of investigational material : trabectedin Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational
0.9mg/m2, 1.2mg/m2, 1.5mg/m2 (Based on the body surface area).

Sponsors

Taiho Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)Patients who have a histologically confirmed soft tissue sarcoma. 2)Patients who have failed the standard therapy. 3)Others.

Exclusion criteria

Exclusion criteria: 1)Serious concomitant illness. 2)Prior therapy-related toxicity. 3)Others.

Design outcomes

Primary

MeasureTime frame
Safety—

Secondary

MeasureTime frame
Pharmacokinetics, Safety, Efficacy—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026